Catalent (CTLT)
(Delayed Data from NYSE)
$55.92 USD
+0.12 (0.22%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $55.90 -0.02 (-0.04%) 7:58 PM ET
5-Strong Sell of 5 5
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.92 USD
+0.12 (0.22%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $55.90 -0.02 (-0.04%) 7:58 PM ET
5-Strong Sell of 5 5
D Value C Growth A Momentum C VGM
Zacks News
Why Is United Therapeutics (UTHR) Up 3.8% Since Last Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
CarParts and Catalent have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
CarParts and Catalent have been highlighted as Zacks Bull and Bear of the Day.
Bear Of The Day: Catalent (CTLT)
by Brian Bolan
Earnings estimates have slipped for this stock following the most recent earnings miss.
Catalent (CTLT) Q1 Earnings Lag Estimates, FY23 View Cut
by Zacks Equity Research
Catalent (CTLT) records robust first-quarter fiscal 2023 results of its Pharma and Consumer Health segment despite overall soft performance.
Catalent (CTLT) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of -38.18% and 4.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks Due to Report Earnings on Nov 1: MCK, CTLT & More
by Debanjana Dey
MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, CTLT, ECL, ABMD, HSIC and IDXX are placed ahead of their earnings releases.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Catalent (CTLT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q1 earnings are likely to have been driven by robust segmental performances.
United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Catalent (CTLT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 14th
by Zacks Equity Research
AHEXY, BLWYY, and CTLT have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2022.
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
Why Is Catalent (CTLT) Down 18.5% Since Last Earnings Report?
by Zacks Equity Research
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.
Catalent (CTLT) Stock Down Despite Q4 Beat: Will it Recover?
by Zacks Equity Research
Catalent's (CTLT) fiscal fourth-quarter earnings beat but the stock falls 7.4% following the earnings release on Aug 29. Here we discuss the factors that are set to guide its share price going forward.
Company News for Aug 30, 2022
by Zacks Equity Research
Companies in The News Are: HTHT,CTLT,MRNA,BA,UPS
Catalent (CTLT) Q4 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
Catalent's (CTLT) robust performance across most of its segments drives its fourth-quarter fiscal 2022 top line.
Catalent (CTLT) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 3.48% and 0.89%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q4 results are likely to have been driven by robust segmental performances.
Here's Why You Should Hold on to Catalent (CTLT) Stock Now
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -110.71% and 63.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Impel Pharmaceuticals Inc. (IMPL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 3.54% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -30.65% and 75.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?